Streetbeat News

Regulatory

ELV

Elevance Health anticipates its 2025 Individual Medicare Advantage membership to grow in line with or slightly better than the broader market. The company is also challenging the initial Star Rating score for one of its larger Medicare Advantage contracts.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:50 pm

SONN

Sonnet BioTherapeutics has regained compliance with Nasdaq's bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:49 pm

KZR

Kezar Life Sciences announced that the PORTOLA trial of zetomipzomib for autoimmune hepatitis will continue without changes, while the PALIZADE trial for lupus nephritis will be discontinued due to safety concerns. The company will focus on developing zetomipzomib for autoimmune hepatitis.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:32 pm

ADIL

Adial Pharmaceuticals has secured a new US patent, expanding its intellectual property protection for its lead drug candidate, AD04, aimed at treating alcohol use disorder. This patent enhances the precision medicine approach by covering additional genotype combinations identified through Adial's genetic diagnostic tool.

Portfolio Pulse from Vandana Singh

October 17, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has expanded its patent estate, which covers its unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:30 pm

ADIL

Adial Pharmaceuticals has received a Notice of Allowance for a U.S. patent covering expanded genotype combinations identified using its genetic diagnostic for addiction treatment. This development could enhance the company's intellectual property portfolio and potentially improve its market position in addiction treatment solutions.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:30 pm

WINT

Windtree Therapeutics has announced the issuance of a new patent for its investigational therapy, istaroxime, in Japan. This patent covers the intravenous administration of istaroxime for treating acute heart failure, with a focus on improving heart function and safety. The patent is valid until 2039.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:18 pm

VGK

The European Central Bank (ECB) has reduced its deposit facility rate from 3.5% to 3.25%. This decision may impact European financial markets and related ETFs.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:18 pm

VGK

The European Central Bank (ECB) has reduced its benchmark refinancing rate from 3.65% to 3.40%. This decision is likely to impact European markets and could influence US-listed ETFs with European exposure.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:16 pm

BABA

JD

PNQI

XNTK

Alibaba and JD.com are easing their rivalry by sharing logistics services in response to economic challenges and regulatory pressures. This collaboration allows merchants on Alibaba's platforms to use JD.com's logistics services, marking a shift towards more open ecosystems. The Chinese government is also considering a significant fiscal stimulus to boost the economy.

Portfolio Pulse from Anusuya Lahiri

October 17, 2024 | 12:13 pm